Основная статистика
| LEI | 254900AQWFD6AR2J7Z30 |
| CIK | 862692 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Cryo-Cell International, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| July 15, 2025 |
Fourth Amendment to Credit Agreement Exhibit 10.6 FOURTH AMENDMENT TO CREDIT AGREEMENT THIS FOURTH AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is executed as of July 15, 2025, to be effective as of July 18, 2025, between CRYO-CELL INTERNATIONAL, INC., a Delaware corporation (“Borrower”), SUSSER BANK, a Texas State Bank, as administrative agent (“Administrative Agent”), and each of the Lenders party hereto. A. Borrower, Administr |
|
| July 15, 2025 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended May 31, 2025 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNATIONAL |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2025 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 8, 2025 |
CORD BLOOD BANKING LEADER CRYO-CELL ANNOUNCES CASH DIVIDEND Exhibit 99.1 For Immediate Release Contact: Irene Smith 813-749-2102 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL ANNOUNCES CASH DIVIDEND OLDSMAR, FL –May 8, 2025 – Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (“Cryo-Cell”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced today that, as a result of the current economic env |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2025 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| April 14, 2025 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended February 28, 2025 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNAT |
|
| February 28, 2025 |
U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended November 30, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNATIONAL, INC. (Exact Name of reg |
|
| November 12, 2024 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Cryo-Cell International, Inc. |
|
| November 12, 2024 |
As filed with the Securities and Exchange Commission on November 12, 2024 As filed with the Securities and Exchange Commission on November 12, 2024 Registration No. |
|
| October 31, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2024 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Com |
|
| October 30, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2024 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Com |
|
| October 30, 2024 |
CORD BLOOD BANKING LEADER CRYO-CELL declares INITIATION OF regular quaRterly CASH DIVIDEND Exhibit 99.1 For Immediate Release Contact: Irene Smith 813-749-2102 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL declares INITIATION OF regular quaRterly CASH DIVIDEND OLDSMAR, FL – October 30, 2024 – Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (“Cryo-Cell”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced today that its |
|
| October 17, 2024 |
CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL THIRD Quarter 2024 FINANCIAL RESULTS Exhibit 99.1 For Immediate Release Contact: Irene Smith 813-749-2102 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL THIRD Quarter 2024 FINANCIAL RESULTS OLDSMAR, FL – October 15, 2024 – Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the |
|
| October 17, 2024 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q/A (Amendment No. 1) U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended August 31, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 001-40767 |
|
| October 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2024 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Com |
|
| October 15, 2024 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended August 31, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNATIO |
|
| October 7, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant: ☒ Filed by a Party other than the Registrant: ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ De |
|
| September 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2024 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (C |
|
| July 15, 2024 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended May 31, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNATIONAL |
|
| July 15, 2024 |
Exhibit 10.5 COMMERCIAL LEASE This Commercial Lease (this " Lease") is entered into as of the 1st day of July 2024 by and between Deborah Portnoy ("Lessor ") and Crvo-Cell International , Inc. ("Lessee "). WITNESSETH: That for and in consideration of the mutual covenants, promises and conditions contained herein, Lessor hereby lets, leases and devises to Lessee, and Lessee does hereby take and acc |
|
| April 15, 2024 |
Master Services Agreement with Emmes Biopharma Services LLC Exhibit 10.5 Master Services Agreement This Master Services Agreement (this “Agreement”) is entered into as of August 10, 2023 (the “Effective Date”), by and between Cryo-Cell International, Inc., (“Customer”) and Emmes Biopharma Services LLC and its Affiliates and Subsidiaries (“Emmes”), a Maryland limited liability company with its principal address in Maryland at 401 North Washington Street, Su |
|
| April 15, 2024 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended February 29, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNAT |
|
| March 26, 2024 |
Exhibit 99.1 For Immediate Release Contact: Irene Smith 813-749-2102 [email protected] CRYO-CELL ANNOUNCES PLANS TO EXPLORE STRATEGIC ALTERNATIVES AND SPIN-OFF CELLE CORP. TO MAXIMIZE SHAREHOLDER VALUE OLDSMAR, FL. – March 25, 2024 – Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company” or “Cryo-Cell”), the world’s first private cord blood bank to separate and store stem cells |
|
| March 26, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2024 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 28, 2024 |
EX-97 CRYO-CELL INTERNATIONAL, INC. CLAWBACK POLICY Introduction The Board of Directors (the “Board”) of Cryo-Cell International, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has, therefore, |
|
| February 28, 2024 |
Third Amendment to Credit Agreement EX-10.66 THIRD AMENDMENT TO CREDIT AGREEMENT THIS THIRD AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is executed as of November 28, 2023 to be effective as of August 31, 2023, between CRYO-CELL INTERNATIONAL, INC., a Delaware corporation (“Borrower”), SUSSER BANK, a Texas State Bank, as administrative agent (“Administrative Agent”), and each of the Lenders party hereto. A. Borrower, Administra |
|
| February 28, 2024 |
U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended November 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNATIONAL, INC. (Exact Name of reg |
|
| October 12, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2023 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Com |
|
| October 12, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended August 31, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNATIO |
|
| September 14, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant: ☒ Filed by a Party other than the Registrant: ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ De |
|
| August 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2023 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Comm |
|
| July 14, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended May 31, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNATIONAL |
|
| April 21, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended February 28, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNAT |
|
| April 14, 2023 |
NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 001-40767 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: February 28, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period Ended: . |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 03, 2023 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 28, 2023 |
Second Amendment to License Agreement SECOND AMENDMENT TO LICENSE AGREEMENT This Second Amendment, dated February 17, 2023 (“Effective Date”), is by and between Cryo-Cell International, Inc. |
|
| February 28, 2023 |
U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended November 30, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNATIONAL, INC. (Exact Name of reg |
|
| February 14, 2023 |
CCEL / CRYO-CELL International, Inc. / ISZO CAPITAL LP Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13D - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 5)* Cryo-Cell International, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 228895108 (CUSIP Number) December 31, 2022 (Date of Ev |
|
| February 3, 2023 |
Cryo-Cell International, Inc. WITHDRAWAL REQUEST VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 February 3, 2023 Re: Cryo-Cell International, Inc. Request for Withdrawal of Registration Statement on Form S-1 File No. 333-264108 CIK No.: 0000862692 Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the Securities A |
|
| December 29, 2022 |
2022 Employment Agreement for Mark Portnoy EX-10.2 3 ccel-ex102.htm EX-10.2 Exhibit 10.2 CRYO-CELL INTERNATIONAL, INC. 2022 EMPLOYMENT AGREEMENT FOR MARK PORTNOY This Employment Agreement (the “Agreement”) is effective as of December 1, 2022 (the “Effective Date”) by and between Cryo-Cell International, Inc. (the “Company”) and Mark Portnoy (the “Executive”). Executive is currently employed as the Co-Chief Executive Officer of the Company, |
|
| December 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2022 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Co |
|
| December 29, 2022 |
2022 Employment Agreement for David Portnoy Exhibit 10.1 CRYO-CELL INTERNATIONAL, INC. 2022 EMPLOYMENT AGREEMENT FOR DAVID PORTNOY This Employment Agreement (the ?Agreement?) is effective as of December 1, 2022 (the ?Effective Date?) by and between Cryo-Cell International, Inc. (the ?Company?) and David Portnoy (the ?Executive?). Executive is currently employed as the Co-Chief Executive Officer of the Company, and the Company and the Execut |
|
| October 18, 2022 |
Amendment to the Credit Agreement between Cryo-Cell International and Susser Bank Exhibit 10.6 AMENDMENT TO CREDIT AGREEMENT THIS AMENDMENT TO CREDIT AGREEMENT (this ?Amendment?) is executed to be effective as of July 29, 2022, between CRYO-CELL INTERNATIONAL, INC., a Delaware corporation (?Borrower?), SUSSER BANK, a Texas State Bank, as administrative agent (?Administrative Agent?), and each of the Lenders party hereto. A. Borrower, Administrative Agent, and Lenders are party |
|
| October 18, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended August 31, 2022 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNATIO |
|
| October 18, 2022 |
Credit Agreement among Cryo-Cell International, Inc. and Susser Bank Exhibit 10.5 CREDIT AGREEMENT among CRYO-CELL INTERNATIONAL, INC., as Borrower THE GUARANTORS FROM TIME TO TIME PARTY HERETO THE LENDERS FROM TIME TO TIME PARTY HERETO and SUSSER BANK, as Administrative Agent DATED AS OF July 18, 2022 TABLE OF CONTENTS Page ARTICLE 1. DEFINITIONS 1 Section 1.1 Definitions 1 Section 1.2 Accounting Matters. 32 Section 1.3 ERISA Matters 33 Section 1.4 Reserved 33 Sec |
|
| October 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: August 31, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on F |
|
| October 5, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 03, 2022 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Com |
|
| September 16, 2022 |
DEF 14A 1 d310686ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant: ☒ Filed by a Party other than the Registrant: ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a |
|
| August 30, 2022 |
OMB APPROVAL OMB Number: 3235-0080 Expires: May 31, 2024 Estimated average burden hours per response 1. |
|
| August 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 CRYO-CELL INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 22-3023093 (State of Incorporation or Organization) (IRS Employer Identification No.) 700 Brooker Creek |
|
| August 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2022 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Comm |
|
| August 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2022 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Comm |
|
| July 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2022 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Commis |
|
| July 11, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended May 31, 2022 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNATIONAL |
|
| April 28, 2022 |
Form of Notes (included as Exhibit A to Exhibit 4.2 above) Exhibit 4.2 Cryo-Cell International, Inc. and U.S. Bank Trust Company, National Association, as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of [May , 2022] to the Indenture dated as of [May , 2022] [ ]% Senior Notes due [20 ] TABLE OF CONTENTS Page ARTICLE 1 APPLICATION OF FIRST SUPPLEMENTAL INDENTURE 1 Section 1.01. Application of First Supplemental Indenture. 1 ARTICLE 2 DEFINITIONS 2 Section |
|
| April 28, 2022 |
Exhibit 4.1 CRYO-CELL INTERNATIONAL, INC. TO U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION AS TRUSTEE INDENTURE DATED AS OF [ , 2022] SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.1 Definitions. 1 Section 1.2 Compliance Certificates and Opinions. 8 Section 1.3 Form of Documents Delivered to Trustee. 9 Section 1.4 Acts of |
|
| April 28, 2022 |
Form of Underwriting Agreement Exhibit 1.1 CRYO-CELL INTERNATIONAL, INC. 8.625% SENIOR NOTES DUE 2026 UNDERWRITING AGREEMENT [ ], 2022 Ladenburg Thalmann & Co. Inc. As representative of the several underwriters c/o Ladenburg Thalmann & Co. Inc. 640 Fifth Avenue, 4th Floor New York, NY 10019 Ladies and Gentlemen: Cryo-Cell International, Inc., a Delaware corporation (the ?Company?), proposes to issue and sell to the several Unde |
|
| April 28, 2022 |
As filed with the Securities and Exchange Commission on April 27, 2022 Table of Contents As filed with the Securities and Exchange Commission on April 27, 2022 Registration No. |
|
| April 27, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q/A (Amendment No. 1) U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended February 28, 2022 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 001-4076 |
|
| April 13, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended February 28, 2022 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNAT |
|
| April 13, 2022 |
Exhibit 10.4 Cryo-Cell International, Inc. 2022 EQUITY INCENTIVE PLAN Article I PURPOSE The purpose of this Cryo-Cell International, Inc. 2022 Equity Incentive Plan (the ?Plan?) is to benefit Cryo-Cell International, Inc., a Delaware corporation (the ?Company?) and its stockholders, by assisting the Company and its subsidiaries to attract, retain and provide incentives to key management employees, |
|
| April 4, 2022 |
As filed with the Securities and Exchange Commission on April 4, 2022 Table of Contents As filed with the Securities and Exchange Commission on April 4, 2022 Registration No. |
|
| April 4, 2022 |
Form T-1 Statement of Eligibility under Trust Indenture Act of 1938, as amended, of Trustee Exhibit 25.1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ? Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 91-1821036 I.R.S. E |
|
| April 4, 2022 |
Exclusive License Agreement with BioE LLC EXHIBIT 10.59 BIOE LICENSE AGREEMENT WITH CRYO-CELL INTERNATIONAL CORD BLOOD TECHNOLOGY EXCLUSIVE LICENSE AGREEMENT THIS EXCLUSIVE LICENSE AGREEMENT (this ?Agreement?), is entered into this 30th day of June, 2015 (the ?Effective Date?), by and among BioE LLC, a Minnesota limited liability company with offices located at 8000 Norman Center Drive, #620, Bloomington, MN 55437 (?Licensor?), Cytomedica |
|
| April 4, 2022 |
First Amendment to Credit Agreement with Texas Capital Bank. Exhibit 10.44 FIRST AMENDMENT TO CREDIT AGREEMENT THIS FIRST AMENDMENT TO CREDIT AGREEMENT (this ?Amendment?) is executed to be effective as of August 26, 2016, between CRYO-CELL INTERNATIONAL, INC., a Delaware corporation (?Borrower?) and TEXAS CAPITAL BANK, NATIONAL ASSOCIATION, a national banking association (?Lender?). A. Borrower and Lender are party to that certain Credit Agreement dated as |
|
| April 4, 2022 |
EXHIBIT 10.61 SERVICES AGREEMENT BY AND BETWEEN CORD:USE Cord Blood Bank, Inc. AND DUKE UNIVERSITY THIS SERVICES AGREEMENT (?Agreement?) is entered into as of July 28, 2017 (?Effective Date?), by and between CORD:USE Cord Blood Bank, Inc., a Florida corporation (?CORD:USE?) and Duke University through its School of Medicine (?Duke?) (each a ?Party? and collectively the ?Parties?). RECITALS WHEREAS |
|
| April 4, 2022 |
Credit Agreement with Texas Capital Bank dated May 20, 2016 Exhibit 10.43 CREDIT AGREEMENT between CRYO-CELL INTERNATIONAL, INC. and TEXAS CAPITAL BANK, NATIONAL ASSOCIATION DATED AS OF May 20, 2016 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 1.1 Definitions 1 1.2 Accounting Matters 10 1.3 ERISA Matters 10 1.4 Other Definitional Provisions 10 ARTICLE 2 ADVANCES AND LETTERS OF CREDIT 10 2.1 Advance 10 2.2 General Provisions Regarding Interest; Etc. 11 2. |
|
| April 4, 2022 |
First Amendment to License Agreement with BioE LLC EXHIBIT 10.60 FIRST AMENDMENT TO LICENSE AGREEMENT THIS FIRST AMENDMENT TO LICENSE AGREEMENT (the ?Amendment?), made this 12th day of July, 2017, by and among BioE LLC, a Minnesota limited liability company with offices located at 8000 Norman Center Drive, #620, Bloomington, MN 55437 (?Licensor?), CytoMedical Design Group LLC, a Minnesota limited liability, and Cryo-Cell International, Inc., a Del |
|
| April 4, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Cryo-Cell International, Inc. |
|
| March 16, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2022 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Commi |
|
| March 16, 2022 |
Exhibit 10.1 PURCHASE AGREEMENT BETWEEN SCANNELL PROPERTIES #502, llc AS SELLER AND CRYO-CELL INTERNATIONAL, INC. AS PURCHASER March 14, 2022 1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (?Agreement?) is made and entered into effective as of March 14, 2022 (the ?Effective Date?) by and among SCANNELL PROPERTIES #502, llc, an Indiana limited liability company (the ?Seller?) and CRYO-CELL INTERNATIO |
|
| March 16, 2022 |
CORD BLOOD BANKING LEADER CRYO-CELL ANNOUNCES EXTRAVAULT BIOREPOSITORY SERVICE Exhibit 99.1 For Immediate Release Contact: Irene Smith 813-749-2102 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL ANNOUNCES EXTRAVAULT BIOREPOSITORY SERVICE OLDSMAR, FL ? March 16, 2022 ? Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (the ?Company?), the world?s first private cord blood bank to separate and store stem cells in 1992, announces it has entered into |
|
| February 24, 2022 |
CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2021 Exhibit 99.1 For Immediate Release Contact: Irene Smith 813-749-2102 [email protected] CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2021 OLDSMAR, FL. ? February 22, 2022 ? Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (the ?Company?), the world?s first private cord blood bank to separate and store stem cells in 1992, announced results for its fis |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2022 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Co |
|
| February 22, 2022 |
First Amendment to License Agreement Exhibit 10.59 FIRST AMENDMENT TO LICENSE AGREEMENT This First Amendment, dated February 4, 2022, is by and between Cryo-Cell International, Inc. (?LICENSEE?) and Duke University ("DUKE"). WHEREAS, LICENSEE and DUKE entered into a license agreement dated February 23 2021 (the "License Agreement"); and WHEREAS, DUKE and LICENSEE desire to modify certain provisions of the License Agreement as provide |
|
| February 22, 2022 |
U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended November 30, 2021 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNATIONAL, INC. (Exact Name of reg |
|
| February 14, 2022 |
CCEL / CRYO-CELL International, Inc. / ISZO CAPITAL LP Passive Investment SC 13G/A 1 cryo13ga4-020421.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13D - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 4)* Cryo-Cell International, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 228895108 (CUSIP Numbe |
|
| January 25, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2022 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Com |
|
| December 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2021 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Co |
|
| October 25, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20 2021 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Comm |
|
| October 15, 2021 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended August 31, 2021 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 001-40767 CRYO-CELL INTERNATIO |
|
| October 15, 2021 |
CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL THIRD Quarter 2021 FINANCIAL RESULTS Exhibit 99.1 For Immediate Release Contact: Irene Smith 813-749-2102 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL THIRD Quarter 2021 FINANCIAL RESULTS OLDSMAR, FL ? October 15, 2021 ? Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (the ?Company?), the world?s first private cord blood bank to separate and store stem cells in 1992, announced results f |
|
| October 15, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2021 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (Com |
|
| October 1, 2021 |
DEF 14A 1 d142568ddef14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant: ☒ Filed by a Party other than the Registrant: ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| September 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2021 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40767 22-3023093 (State or Other Jurisdiction of Incorporation) (C |
|
| September 22, 2021 |
Cryo-Cell International Announces Changes To Its Board of Directors ? Exhibit 99.1 Cryo-Cell International Announces Changes To Its Board of Directors Miami, Fl, September 20, 2021 (GLOBENEWSWIRE) - Cryo-Cell International, Inc. (Nasdaq:CCEL), the leader in cord blood and cord tissue cryopreservation services, announces the appointment of Mr. Mark Portnoy and Mr. Daniel Mizrahi to the Company?s Board of Directors, replacing Mr. George Gaines and Jonathan Wheeler, |
|
| August 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 CRYO-CELL INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 22-3023093 (State of Incorporation or Organization) (IRS Employer Identification No.) 700 Brooker Creek |
|
| August 4, 2021 |
2021 Employment Agreement for Oleg Mikulinsky Exhibit 10.1 CRYO-CELL INTERNATIONAL, INC. 2021 EMPLOYMENT AGREEMENT FOR OLEG MIKULINSKY This Employment Agreement (the ?Agreement?) is effective as of August 1, 2021 (the ?Effective Date?) by and between Cryo-Cell International, Inc. (the ?Company?) and Oleg Mikulinsky ( the ?Executive?). Executive is currently employed as the Chief Information Officer of the Company, and the Company and the Exec |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-23386 22-3023093 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| July 19, 2021 |
CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND Quarter 2021 FINANCIAL RESULTS Exhibit 99.1 For Immediate ReleaseContact: Diane Glanz, Rph, PharmD Investor Relations Consultant 813-749-2195 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND Quarter 2021 FINANCIAL RESULTS OLDSMAR, FL ? July 15, 2021 ? Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the ?Company?), the world?s first private cord blood bank to separate and store st |
|
| July 19, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2021 CRYO-CELL INTERNATIONAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-23386 22-3023093 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| July 15, 2021 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended May 31, 2021 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 0-23386 CRYO-CELL INTERNATIONAL, |
|
| June 30, 2021 |
2020 Employment Agreement for David Portnoy Exhibit 10.1 CRYO-CELL INTERNATIONAL, INC. 2020 EMPLOYMENT AGREEMENT FOR DAVID PORTNOY This Employment Agreement (the ?Agreement?) is effective as of December 1, 2020 (the ?Effective Date?) by and between Cryo-Cell International, Inc. (the ?Company?) and David Portnoy (the ?Executive?). Executive is currently employed as the Co-Chief Executive Officer of the Company, and the Company and the Execut |
|
| June 30, 2021 |
2020 Employment Agreement for Mark Portnoy Exhibit 10.2 CRYO-CELL INTERNATIONAL, INC. 2020 EMPLOYMENT AGREEMENT FOR MARK PORTNOY This Employment Agreement (the ?Agreement?) is effective as of December 1, 2020 (the ?Effective Date?) by and between Cryo-Cell International, Inc. (the ?Company?) and Mark Portnoy (the ?Executive?). Executive is currently employed as the Co-Chief Executive Officer of the Company, and the Company and the Executiv |
|
| June 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2021 CRYO-CELL INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 0-23386 22-3023093 (State or other jurisdiction of incorporation) (Commissi |
|
| April 16, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2021 CRYO-CELL INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 0-23386 22-3023093 (State or other jurisdiction of incorporation) (Commiss |
|
| April 16, 2021 |
CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIrst Quarter 2021 FINANCIAL RESULTS Exhibit 99.1 For Immediate ReleaseContact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIrst Quarter 2021 FINANCIAL RESULTS OLDSMAR, FL – April 14, 2021 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord bloo |
|
| April 14, 2021 |
Patent and License Technology Agreement Exhibit 10.2 PATENT AND TECHNOLOGY LICENSE AGREEMENT DUKE UNIVERSITY AND CRYO-CELL INTERNATIONAL, INC. EFFECTIVE February 23, 2021 1 Table of Contents ARTICLE 1 - DEFINITIONS 3 ARTICLE 2 - GRANT OF LICENSE 7 ARTICLE 3 - CONSIDERATION 9 ARTICLE 4 - REPORTS 14 ARTICLE 5 - DILIGENCE 16 ARTICLE 6 - SUBLICENSING 19 ARTICLE 7 - PATENT APPLICATIONS AND MAINTENANCE 20 ARTICLE 8 - ENFORCEMENT 21 ARTICLE 9 |
|
| April 14, 2021 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended February 28, 2021 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 0-23386 CRYO-CELL INTERNATIO |
|
| March 1, 2021 |
U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended November 30, 2020 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number 000-23386 CRYO-CELL INTERNATIONAL, INC. (Exact Name of reg |
|
| February 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 24, 2021 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation) (Co |
|
| February 25, 2021 |
CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2020 Exhibit 99.1 For Immediate ReleaseContact: David Portnoy Cryo-Cell International, Inc. 813-749-2100 [email protected] CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2020 OLDSMAR, FL. ? February 24, 2021 ? Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the ?Company?), the world?s first private cord blood bank to separate and store stem cells in 1992, |
|
| February 16, 2021 |
SC 13G/A 1 cryo13ga3-021621.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13D - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 3)* Cryo-Cell International, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 228895108 (CUSIP Numbe |
|
| December 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2020 CRYO-CELL INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 0-23386 22-3023093 (State or other jurisdiction of incorporation) (Commi |
|
| October 19, 2020 |
CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL THIRD Quarter 2020 FINANCIAL RESULTS Exhibit 99.1 For Immediate ReleaseContact: David Portnoy, Chairman and Co-CEO Cryo-Cell International, Inc. 813-749-2100 CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL THIRD Quarter 2020 FINANCIAL RESULTS OLDSMAR, FL – October 15, 2020 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells |
|
| October 19, 2020 |
Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 15, 2020 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation) (Com |
|
| October 15, 2020 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended August 31, 2020 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 0-23386 CRYO-CELL INTERNATIONA |
|
| September 23, 2020 |
Submission of Matters to a Vote of Security Holders - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 22, 2020 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation |
|
| September 8, 2020 |
SEC Response Letter Bank of America Plaza 101 East Kennedy Boulevard Suite 2800 Tampa, Florida 33602 813. |
|
| September 8, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 31, 2020 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation) ( |
|
| September 1, 2020 |
DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14A-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant: ☒ Filed by a Party other than the Registrant: ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| August 11, 2020 |
Shareholder Director Nominations 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 CRYO-CELL INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 0-23386 22-3023093 (State or other jurisdiction of incorporation) (Com |
|
| July 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 10, 2020 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation) (Co |
|
| July 13, 2020 |
CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND QUARTER 2020 FINANCIAL RESULTS EX-99.1 Exhibit 99.1 For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND QUARTER 2020 FINANCIAL RESULTS OLDSMAR, FL – July 10, 2020 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private |
|
| July 10, 2020 |
10-Q Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended May 31, 2020 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 0-23386 CR |
|
| June 11, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2020 CRYO-CELL INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 0-23386 22-3023093 (State or other jurisdiction of incorporation) (Commi |
|
| June 11, 2020 |
CORD BLOOD BANKING LEADER CRYO-CELL ENTERS INTO PATENT OPTION AGREEMENT WITH DUKE UNIVERSITY EX-99.1 3 d943128dex991.htm EX-99.1 Exhibit 99.1 For Immediate Release Contact: David Portnoy, Chairman and Co-CEO Cryo-Cell International, Inc. 813-749-2100 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL ENTERS INTO PATENT OPTION AGREEMENT WITH DUKE UNIVERSITY OLDSMAR, FL – June 11, 2020 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s f |
|
| June 11, 2020 |
EX-10.1 Exhibit 10.1 PATENT OPTION AGREEMENT Duke University File(s) #4719, 5000, 5191, 5204, 6381, 6382, 6478, 6479, 6480, 6622, 6623, 6624, 6625 and 7094 This Patent Option Agreement (“Agreement”) is entered into on June 9, 2020 (“EFFECTIVE DATE”), between Duke University, a nonprofit educational and research institution organized under the laws of North Carolina (“DUKE”) having the address in A |
|
| May 6, 2020 |
CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2020 FINANCIAL RESULTS EX-99.1 Exhibit 99.1 For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2020 FINANCIAL RESULTS OLDSMAR, FL – April 14, 2020 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private |
|
| May 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 14, 2020 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation) (C |
|
| April 14, 2020 |
CCEL / CRYO-CELL International, Inc. 10-Q - Quarterly Report - 10-Q 10-Q Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended February 29, 2020 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 0-233 |
|
| March 2, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 27, 2020 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation) |
|
| March 2, 2020 |
CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2019 EX-99.1 Exhibit 99.1 For Immediate Release Contact: David Portnoy Cryo-Cell International, Inc. 813-749-2100 [email protected] CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2019 OLDSMAR, FL. – February 27, 2020 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells |
|
| February 28, 2020 |
CCEL / CRYO-CELL International, Inc. 10-K - Annual Report - 10-K 10-K 1 d807043d10k.htm 10-K Table of Contents U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended November 30, 2019 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number 000-23386 CR |
|
| February 14, 2020 |
SC 13G/A 1 cryocell13ga2-123119.htm AMENDMENT NO. 2 TO THE SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13D - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 2)* Cryo-Cell International, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Cla |
|
| November 27, 2019 |
Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 21, 2019 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation) |
|
| October 29, 2019 |
Retrospective Amendments to the 2000 Stock Incentive Plan DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14A-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant: ☒ Filed by a Party other than the Registrant: ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| October 17, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 15, 2019 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation) |
|
| October 17, 2019 |
CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL THIRD QUARTER 2019 FINANCIAL RESULTS EX-99.1 Exhibit 99.1 For Immediate Release Contact: David Portnoy, Chairman and Co-CEO Cryo-Cell International, Inc. 813-749-2100 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL THIRD QUARTER 2019 FINANCIAL RESULTS OLDSMAR, FL – October 15, 2019 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank t |
|
| October 15, 2019 |
CCEL / CRYO-CELL International, Inc. 10-Q - Quarterly Report - 10-Q 10-Q Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended August 31, 2019 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 0-23386 |
|
| October 11, 2019 |
CCEL / CRYO-CELL International, Inc. PRE 14A - - PRE 14A PRE 14A 1 d779709dpre14a.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14A-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant: ☒ Filed by a Party other than the Registrant: ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as p |
|
| October 9, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2019 CRYO-CELL INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 0-23386 22-3023093 (State or other jurisdiction of incorporation) (Co |
|
| October 2, 2019 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 1, 2019 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation) ( |
|
| October 2, 2019 |
EX-16.1 2 d597710dex161.htm EX-16.1 Exhibit 16.1 October 2, 2019 Securities and Exchange Commission Washington, D.C. 20549 Commissioners: We have read CRYO CELL International, Inc.‘s statements included under Item 4.01 of its Form 8-K filed on October 2, 2019 and we agree with such statements concerning our firm. /s/ Wipfli LLP |
|
| July 25, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 15, 2019 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation) (Co |
|
| July 25, 2019 |
CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND QUARTER 2019 FINANCIAL RESULTS EX-99.1 Exhibit 99.1 For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND QUARTER 2019 FINANCIAL RESULTS OLDSMAR, FL – July 15, 2019 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private |
|
| July 15, 2019 |
CCEL / CRYO-CELL International, Inc. 10-Q - Quarterly Report - FORM 10-Q Form 10-Q Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended May 31, 2019 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 0-233 |
|
| April 16, 2019 |
CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2019 FINANCIAL RESULTS EX-99.1 2 d632379dex991.htm EX-99.1 Exhibit 99.1 For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2019 FINANCIAL RESULTS OLDSMAR, FL – April 15, 2019 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”) |
|
| April 16, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 15, 2019 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation) (C |
|
| April 15, 2019 |
CCEL / CRYO-CELL International, Inc. 10-Q (Quarterly Report) 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended February 28, 2019 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 0-23386 CRYO-CELL INTER |
|
| March 1, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2019 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation) |
|
| March 1, 2019 |
CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2018 EX-99.1 2 d711858dex991.htm EX-99.1 Exhibit 99.1 For Immediate Release Contact: David Portnoy Cryo-Cell International, Inc. 813-749-2100 [email protected] CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2018 OLDSMAR, FL. – February 28, 2019 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to s |
|
| February 28, 2019 |
CCEL / CRYO-CELL International, Inc. 10-K (Annual Report) 10-K Table of Contents U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended November 30, 2018 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number 000-23386 CRYO-CELL INTERNATIONAL, |
|
| February 14, 2019 |
CCEL / CRYO-CELL International, Inc. / ISZO CAPITAL LP - FEBRUARY 14, 2019 Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13D - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No.1)* Cryo-Cell International, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 228895108 (CUSIP Number) December 31, 2018 (Date of Eve |
|
| December 11, 2018 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF CRYO-CELL INTERNATIONAL, INC. (As Amended Through December 6, 2018) ARTICLE I OFFICES The registered office of the Corporation shall be located in the City, County and State so provided in the Certificate of Incorporation. The Corporation may also maintain offices at such other places within or without the State of Delaware as the Board of Director |
|
| December 11, 2018 |
8-K 1 d673855d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2018 CRYO-CELL INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 0-23386 22-3023093 (State or other jurisdi |
|
| October 22, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 15, 2018 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation) |
|
| October 22, 2018 |
CRYO-CELL REPORTS FISCAL THIRD QUARTER 2018 RESULTS EX-99.1 Exhibit 99.1 For Immediate Release Contact: David Portnoy, Chairman and Co-CEO Cryo-Cell International, Inc. 813-749-2100 [email protected] CRYO-CELL REPORTS FISCAL THIRD QUARTER 2018 RESULTS OLDSMAR, FL – October 15, 2018 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1 |
|
| October 15, 2018 |
CCEL / CRYO-CELL International, Inc. FORM 10-Q (Quarterly Report) Form 10-Q Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended August 31, 2018 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 0- |
|
| August 30, 2018 |
EX-99.1 Exhibit 99.1 CORD:USE Cord Blood Bank, Inc. Financial Statements December 31, 2017 and 2016 With Independent Auditors’ Report CORD:USE Cord Blood Bank, Inc. December 31, 2017 and 2016 TABLE OF CONTENTS Independent Auditors’ Report 1-2 Financial Statements Balance Sheets 3 Statements of Operations 4 Statements Shareholders’ Equity 5 Statements of Cash Flows 6 Notes to Financial Statements 7 |
|
| August 30, 2018 |
EX-99.2 Exhibit 99.2 CORD:USE Cord Blood Bank, Inc. BALANCE SHEETS (Unaudited) March 31, December 31, 2018 2017 ASSETS Current Assets Cash $ 555,214 $ 54,150 Accounts receivable (net of allowance for doubtful accounts of $26,000 and $21,000, respectively) 215,827 165,430 Inventory, net 15,898,037 15,786,457 Prepaid expenses and other current assets 183,476 291,053 Total current assets 16,852,554 1 |
|
| August 30, 2018 |
Financial Statements and Exhibits Form 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2018 CRYO-CELL INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 0-23386 22-3023093 (State or other jurisdict |
|
| August 30, 2018 |
Consent of Withium Smith & Brown, PC EX-21.1 2 d611526dex211.htm EX-21.1 Exhibit 21.1 INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT We hereby consent to the incorporation by reference of our report on the December 31, 2017 and 2016 financial statements of Cord: Use Cord Blood Bank, Inc., dated May 29, 2018, included in this Current Report on Form 8-K/A, into the Registration Statement on Form S-8 (File No. 333-197483) of Cr |
|
| August 30, 2018 |
EX-99.3 Exhibit 99.3 Cryo-Cell International, Inc. (“the Company” or “Cryo-Cell”) entered into an asset purchase agreement with Cord:Use Cord Blood Bank, Inc., (“Cord:Use”), pursuant to which the Company acquired certain assets from Cord:Use for total consideration of $14,000,000 on June 11, 2018 (“Acquisition”). The unaudited preliminary proforma condensed combined balance sheet as of February 28 |
|
| August 16, 2018 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 13, 2018 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporati |
|
| August 16, 2018 |
ARTHUR ELLIS AND BRIAN SHEEHY JOIN CRYO-CELL’S BOARD OF DIRECTORS EX-99.1 3 d603377dex991.htm EX-99.1 Exhibit 99.1 For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 [email protected] ARTHUR ELLIS AND BRIAN SHEEHY JOIN CRYO-CELL’S BOARD OF DIRECTORS OLDSMAR, FL – August 16, 2018 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first p |
|
| August 16, 2018 |
Agreement between the Company and Messrs. Ellis and Sheehy Exhibit 10.1 AGREEMENT This Agreement, dated as of August 13, 2018 (this “Agreement”), is by and among Brian Sheehy (“Sheehy”), Arthur Ellis (“Ellis”), and Cryo-Cell International, Inc. (the “Company”). NOW, THEREFORE, in consideration of and reliance upon the mutual covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are h |
|
| July 26, 2018 |
CCEL / CRYO-CELL International, Inc. DEF 14A DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14A-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant: ☒ Filed by a Party other than the Registrant: ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| July 17, 2018 |
CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND QUARTER 2018 FINANCIAL RESULTS EX-99.1 Exhibit 99.1 For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND QUARTER 2018 FINANCIAL RESULTS OLDSMAR, FL – July 16, 2018 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private |
|
| July 17, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 16, 2018 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation) (Co |
|
| July 16, 2018 |
CCEL / CRYO-CELL International, Inc. 10-Q (Quarterly Report) 10-Q Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended May 31, 2018 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 0-23386 CR |
|
| June 21, 2018 |
CCEL / CRYO-CELL International, Inc. / Cu Blood, Inc. - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Act of 1934 (Amendment No. ) CRYO-CELL INTERNATIONAL, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 228895108 (CUSIP Number) June 11, 2018 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to |
|
| June 15, 2018 |
Second Amendment to Credit Agreement with Texas Capital Bank dated June 11, 2018. EX-2.2 Exhibit 2.2 SECOND AMENDMENT TO CREDIT AGREEMENT THIS SECOND AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is executed to be effective as of June 11, 2018, between CRYO-CELL INTERNATIONAL, INC., a Delaware corporation (“Borrower”) and TEXAS CAPITAL BANK, NATIONAL ASSOCIATION, a national banking association (“Lender”). A. Borrower and Lender are party to that certain Credit Agreement date |
|
| June 15, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2018 CRYO-CELL INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 0-23386 22-3023093 (State or other jurisdiction of incorporation) (Commissi |
|
| June 15, 2018 |
Second Amended and Restated Promissory Note dated June 11, 2018 EX-2.3 3 d599145dex23.htm EX-2.3 Exhibit 2.3 SECOND AMENDED AND RESTATED PROMISSORY NOTE $15,499,999.81 June 11, 2018 FOR VALUE RECEIVED, CRYO-CELL INTERNATIONAL, INC., a Delaware corporation (“Borrower”), having an address at 700 Brooker Creek Blvd., Suite 1800, Oldsmar, FL 34677, hereby promises to pay to the order of TEXAS CAPITAL BANK, NATIONAL ASSOCIATION, a national banking association (toge |
|
| June 15, 2018 |
EX-99.1 4 d599145dex991.htm EX-99.1 Exhibit 99.1 For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 [email protected] CRYO-CELL CONSUMMATES ACQUISITION OF CORD:USE ASSETS AND EXTENDS ITS LEADERSHIP POSITION INTO THE PUBLIC CORD BLOOD BANKING ARENA OLDSMAR, Fla. – June 15, 2018 – Cryo-Cell International, Inc. (OTC:QB |
|
| June 4, 2018 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2018 CRYO-CELL INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 0-23386 22-3023093 (State or other jurisdiction of incorporation) ( |
|
| June 4, 2018 |
EX-2.1 2 d587398dex21.htm EX-2.1 Exhibit 2.1 Execution Copy ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (this “Agreement”), dated as of May 29, 2018, is entered into between Cord:Use Cord Blood Bank, Inc., a Florida corporation (“Seller”) and Cryo-Cell International, Inc., a Delaware corporation (“Buyer”). RECITALS WHEREAS, Seller is engaged in the business of public and private cord bl |
|
| June 4, 2018 |
CORD BLOOD BANKING LEADER CRYO-CELL ACQUIRES CORD:USE CORD BLOOD BANK, INC. EX-99.1 3 d587398dex991.htm EX-99.1 Exhibit 99.1 For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL ACQUIRES CORD:USE CORD BLOOD BANK, INC. OLDSMAR, Fla. – June 4, 2018 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’ |
|
| May 24, 2018 |
Amended Agreement with Oleg Mikulinsky effective December 1, 2017. EX-10.1 2 d591479dex101.htm EX-10.1 Exhibit 10.1 AMENDMENT AGREEMENT This Amendment Agreement is entered into and effective as of December 1, 2017, by and between Cryo-Cell International, Inc. (the “Company”) and Oleg Mikulinsky (the “Executive”). RECITALS A. The Company and the Executive entered into an Employment Agreement dated March 5, 2012 (the “Employment Agreement”). B. The initial term of |
|
| May 24, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 21, 2018 Cryo-Cell International, Inc. (Exact name of registrant as specified in its charter) Delaware 0-23386 22-3023093 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 18, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2018 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation) |
|
| April 18, 2018 |
CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2018 FINANCIAL RESULTS EX-99.1 Exhibit 99.1 For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2018 FINANCIAL RESULTS OLDSMAR, Fla. – April 16, 2018 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first privat |
|
| April 16, 2018 |
CCEL / CRYO-CELL International, Inc. 10-Q (Quarterly Report) 10-Q Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended February 28, 2018 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 0-233 |
|
| March 13, 2018 |
Stockholder Agreement between Cryo-Cell International, Inc. and George Gaines EX-10.3 Exhibit 10.3 CRYO-CELL INTERNATIONAL, INC. STOCKHOLDERS AGREEMENT PREAMBLE This Stockholders Agreement, by and among Cryo-Cell International, Inc., a Delaware corporation (the “Company”) and George C. Gaines, Jr., is entered into this 12th day of March, 2018. WHEREAS, the outside and independent directors of the Company have determined (a) that equity-based compensation for management and |
|
| March 13, 2018 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 9, 2018 Cryo-Cell International, Inc. (Exact name of registrant as specified in its charter) Delaware 0-23386 22-3023093 (State or Other Jurisdiction of Incorporation) (Comm |
|
| March 13, 2018 |
Stockholder Agreement between Cryo-Cell International, Inc. and David Portnoy Exhibit 10.4 CRYO-CELL INTERNATIONAL, INC. STOCKHOLDERS AGREEMENT PREAMBLE This Stockholders Agreement, by and among Cryo-Cell International, Inc., a Delaware corporation (the “Company”) and David I. Portnoy, is entered into this 12th day of March, 2018. WHEREAS, the outside and independent directors of the Company have determined (a) that equity-based compensation for management and directors red |
|
| March 13, 2018 |
Amended and restated Employment Agreement with David Portnoy dated March 8, 2018. EX-10.1 2 d539529dex101.htm EX-10.1 Exhibit 10.1 CRYO-CELL INTERNATIONAL, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT FOR DAVID PORTNOY This Amended and Restated Employment Agreement (the “Agreement”) is made and is effective as of December 1, 2017 (the “Effective Date”) by and between Cryo-Cell International, Inc. (the “Company”) and David Portnoy (“Executive”). WHEREAS, Executive is currently |
|
| March 13, 2018 |
Stockholder Agreement between Cryo-Cell International, Inc. and Mark Portnoy EX-10.5 Exhibit 10.5 CRYO-CELL INTERNATIONAL, INC. STOCKHOLDERS AGREEMENT PREAMBLE This Stockholders Agreement, by and among Cryo-Cell International, Inc., a Delaware corporation (the “Company”) and Mark L. Portnoy, is entered into this 12th day of March, 2018. WHEREAS, the outside and independent directors of the Company have determined (a) that equity-based compensation for management and direct |
|
| March 13, 2018 |
Amended and restated Employment Agreement with Mark Portnoy dated March 8, 2018. EX-10.2 Exhibit 10.2 CRYO-CELL INTERNATIONAL, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT FOR MARK PORTNOY This Amended and Restated Employment Agreement (the “Agreement”) is made and is effective as of December 1, 2017 (the “Effective Date”) by and between Cryo-Cell International, Inc. (the “Company”) and Mark Portnoy (“Executive”). WHEREAS, Executive is currently employed as the Co-Chief Exec |
|
| March 1, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2018 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation) |
|
| March 1, 2018 |
CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2017 EX-99.1 2 d542982dex991.htm EX-99.1 Exhibit 99.1 For Immediate Release Contact: David Portnoy Cryo-Cell International, Inc. 813-749-2100 [email protected] CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2017 OLDSMAR, FL. – February 28, 2018 – Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to s |
|
| February 28, 2018 |
CCEL / CRYO-CELL International, Inc. 10-K (Annual Report) 10-K Table of Contents U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended November 30, 2017 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number 000-23386 CRYO-CELL INTERNATIONAL, |
|
| February 15, 2018 |
CBAI / Cord Blood America, Inc. / CRYO CELL INTERNATIONAL INC - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Amendment No. 3 Under the Securities Exchange Act of 1934 Cord Blood America, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 21839P206 (Cusip Number) Steven Lanter, Esq. Luse Gorman, PC 5335 Wisconsin Avenue, NW, Suite 780 Washington, D.C. 20015 (202) 274-20 |
|
| February 14, 2018 |
CCEL / CRYO-CELL International, Inc. / ISZO CAPITAL LP - FEBRUARY 14, 2018 Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13D - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No.)* Cryo-Cell International, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 228895108 (CUSIP Number) December 31, 2017 (Date of Even |
|
| January 19, 2018 |
SC 13G Amendment No. 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* CRYO-CELL INTERNATIONAL, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 228895108 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| October 17, 2017 |
CRYO-CELL REPORTS FISCAL THIRD QUARTER 2017 RESULTS Exhibit 99.1 For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 [email protected] CRYO-CELL REPORTS FISCAL THIRD QUARTER 2017 RESULTS OLDSMAR, Fla. October 16, 2017 Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the Company), the worlds first private cord blood bank to separate and store st |
|
| October 17, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 16, 2017 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporat |
|
| October 17, 2017 |
CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND QUARTER 2017 FINANCIAL RESULTS EX-99.1 Exhibit 99.1 For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND QUARTER 2017 FINANCIAL RESULTS OLDSMAR, Fla. ? July 7, 2017 ? Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the ?Company?), the world?s first private |
|
| October 17, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 7, 2017 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation) |
|
| October 16, 2017 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q 10-Q Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended August 31, 2017 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 0-23386 |
|
| July 18, 2017 |
Submission of Matters to a Vote of Security Holders Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 18, 2017 CRYO-CELL INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-23386 22-3023093 (State or Other Jurisdiction of Incorporation) |
|
| July 7, 2017 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended May 31, 2017 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 0-23386 CRYO-CELL INTERNATIONAL, |
|
| June 26, 2017 |
CRYO-CELL International DEFINITIVE PROXY STATEMENT Definitive Proxy Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 17, 2017 |
CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2017 FINANCIAL RESULTS Press Release Exhibit 99.1 For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2017 FINANCIAL RESULTS OLDSMAR, Fla. ? April 14, 2017 ? Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the ?Company?), the world?s first |
|
| April 17, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 14, 2017 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporatio |
|
| April 13, 2017 |
CRYO-CELL International FORM 10-Q (Quarterly Report) 10-Q 1 d365977d10q.htm FORM 10-Q Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended February 28, 2017 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to |
|
| March 6, 2017 |
CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL 2016 Press Release Exhibit 99.1 For Immediate Release Contact: David Portnoy Cryo-Cell International, Inc. 813-749-2100 [email protected] CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL 2016 OLDSMAR, Fla. ? February 28, 2017 ? Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the ?Company?), the world?s first private cord blood bank to separate and store stem cells in 1992, announc |
|
| March 6, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2017 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorpora |
|
| February 28, 2017 |
CCEL / CRYO-CELL International, Inc. 10-K - Annual Report - FORM 10-K 10-K 1 d272195d10k.htm FORM 10-K Table of Contents U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended November 30, 2016 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number 000-233 |
|
| February 14, 2017 |
Schedule 13G Amendment No. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* CRYO-CELL INTERNATIONAL, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 228895108 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check |
|
| November 3, 2016 |
EX-4.1 2 d285464dex41.htm AMENDMENT TO THE RIGHTS AGREEMENT Exhibit 4.1 AMENDMENT TO RIGHTS AGREEMENT Amendment to Rights Agreement (this “Amendment”), dated as of October, 31, 2016, between Cryo-Cell International, Inc., a Delaware corporation (the “Company”), and Continental Stock and Transfer Trust (the “Rights Agent”). Whereas, the Company entered into that certain Rights Agreement with the Ri |
|
| November 3, 2016 |
Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 31, 2016 CRYO-CELL INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-23386 22-3023093 (State or Other Jurisdiction of Incorporation) (Commi |
|
| October 17, 2016 |
CCEL / CRYO-CELL International, Inc. 10-Q - Quarterly Report - FORM 10-Q Form 10-Q Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended August 31, 2016 ¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 0- |
|
| October 13, 2016 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 6, 2016 CRYO-CELL INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-23386 22-3023093 (State or Other Jurisdiction of Incorporation |
|
| August 30, 2016 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 26, 2016 CRYO-CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporati |
|
| August 1, 2016 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 27, 2016 CRYO-CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation |
|
| July 12, 2016 |
CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND QUARTER 2016 FINANCIAL RESULTS Press Release Exhibit 99.1 For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND QUARTER 2016 FINANCIAL RESULTS OLDSMAR, Fla. ? July 11, 2016 ? Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the ?Company?), the world?s first |
|
| July 12, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 11, 2016 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation |
|
| July 11, 2016 |
CCEL / CRYO-CELL International, Inc. 10-Q - Quarterly Report - FORM 10-Q 10-Q 1 d122646d10q.htm FORM 10-Q Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended May 31, 2016 ¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commi |
|
| July 7, 2016 |
Submission of Matters to a Vote of Security Holders Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 6, 2016 CRYO-CELL INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-23386 22-3023093 (State or Other Jurisdiction of Incorporation) ( |
|
| July 1, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 1, 2016 CRYO-CELL INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-23386 22-3023093 (State or Other Jurisdiction of Incorporation) ( |
|
| June 24, 2016 |
Stock Purchase Agreement dated June 16, 2016. Exhibit 2 STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (the ?Agreement?) is made and entered into as of the 16th day of June, 2016, by and between, on the one hand, Ki Yong Choi (?Choi?) and Michael Cho (?Cho? and, with Choi, collectively, ?Sellers?), and, on the other hand, Cryo-Cell International, Inc. |
|
| June 24, 2016 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 20, 2016 CRYO-CELL INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-23386 22-3023093 (State or Other Jurisdiction of Incorporation) |
|
| June 21, 2016 |
CRYO-CELL International DEFINITIVE PROXY STATEMENT Definitive Proxy Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 26, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 26, 2016 CRYO-CELL INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-23386 22-3023093 (State or Other Jurisdiction of Incorporation) ( |
|
| May 26, 2016 |
Amended and Restated Bylaws Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF CRYO-CELL INTERNATIONAL, INC. (As Amended Through March 9, 2016) ARTICLE I OFFICERS The principal office of the Corporation shall be located in the City, County and State so provided in the Certificate of Incorporation. The Corporation may also maintain offices at such other places within or without the State of Delaware as the |
|
| April 20, 2016 |
8-K 1 d174850d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 18, 2016 Cryo-Cell International, Inc. (Exact name of registrant as specified in its charter) Delaware 0-23386 22-3023093 (State or Other Jurisdict |
|
| April 20, 2016 |
Amendment Agreement with Oleg Mikulinsky dated December 1, 2015. EX-10.1 2 d174850dex101.htm EMPLOYMENT AGREEMENT BETWEEN CRYO-CELL INTERNATIONAL, INC. AND OLEG MIKULINSKY EXHIBIT 10.1 AMENDMENT AGREEMENT This Amendment Agreement is entered into and effective as of December 1, 2015, by and between Cryo-Cell International, Inc. (the “Company”) and Oleg Mikulinsky (the “Executive”). RECITALS A. The Company and the Executive entered into an Employment Agreement da |
|
| April 19, 2016 |
Amended and Restated Employment Agreement with David Portnoy dated December 1, 2015 EX-10.1 2 d132960dex101.htm EMPLOYMENT AGREEMENT BETWEEN CRYO-CELL INTERNATIONAL, INC. AND DAVID PORTNOY EXHIBIT 10.1 CRYO-CELL INTERNATIONAL, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT FOR DAVID PORTNOY This Amended and Restated Employment Agreement (the “Agreement”) is made as of December 1, 2015 (the “Effective Date”) by and between Cryo-Cell International, Inc. (the “Company”) and David Po |
|
| April 19, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 15, 2016 Cryo-Cell International, Inc. (Exact name of registrant as specified in its charter) Delaware 0-23386 22-3023093 (State or Other Jurisdiction of Incorporation) |
|
| April 19, 2016 |
Amended and Restated Employment Agreement with David Portnoy dated December 1, 2015 Employment Agreement between Cryo-Cell International, Inc. and Mark Portnoy EXHIBIT 10.2 CRYO-CELL INTERNATIONAL, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT FOR MARK PORTNOY This Amended and Restated Employment Agreement (the ?Agreement?) is made as of December 1, 2015 (the ?Effective Date?) by and between Cryo-Cell International, Inc. (the ?Company?) and Mark Portnoy (?Executive?). WHEREAS, E |
|
| April 14, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 14, 2016 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporatio |
|
| April 14, 2016 |
CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2016 FINANCIAL RESULTS Press Release Exhibit 99.1 For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 [email protected] CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2016 FINANCIAL RESULTS OLDSMAR, Fla. ? April 14, 2016 ? Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the ?Company?), the world?s first |
|
| April 14, 2016 |
CCEL / CRYO-CELL International, Inc. 10-Q - Quarterly Report - FORM 10-Q Form 10-Q Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended February 29, 2016 ¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number |
|
| April 13, 2016 |
SC 13D/A 1 d160768dsc13da.htm AMENDMENT NO. 2 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Amendment No. 2 Under the Securities Exchange Act of 1934 Cord Blood America, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 21839P206 (Cusip Number) Steven Lanter, Esq. Luse Gorman, PC 5335 Wisconsin Aven |
|
| March 18, 2016 |
Amended Bylaws Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF CRYO-CELL INTERNATIONAL, INC. (As Amended Through March 9, 2016) ARTICLE I OFFICERS The principal office of the Corporation shall be located in the City, County and State so provided in the Certificate of Incorporation. The Corporation may also maintain offices at such other places within or without the State of Delaware as the Board of Dir |
|
| March 18, 2016 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2016 CRYO-CELL International, Inc. (Exact name of registrant as specified in its charter) Delaware 0-23386 22-3023093 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 18, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 17, 2016 CRYO-CELL INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-23386 22-3023093 (State or Other Jurisdiction of Incorporation) |
|
| March 18, 2016 |
Youâve Exceeded the SECâs Traffic Limit Letter from Grant Thornton LLP Exhibit 16.1 March 18, 2016 Grant Thornton LLP U.S. Securities and Exchange Commission Office of the Chief Accountant 100 F Street, NE Washington, DC 20549 Re: Cryo-Cell International, Inc. File No. 0-23386 Dear Sir or Madam: We have read Item 4.01 of Form 8-K of Cryo-Cell International, Inc. dated March 15, 2016, and agree with the statements concerning our Firm con |
|
| March 14, 2016 |
Amended Bylaws Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF CRYO-CELL INTERNATIONAL, INC. (As Amended Through March 9, 2016) ARTICLE I OFFICERS The principal office of the Corporation shall be located in the City, County and State so provided in the Certificate of Incorporation. The Corporation may also maintain offices at such other places within or without the State of Delaware as the Board of Dir |
|
| March 14, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 9, 2016 CRYO-CELL INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-23386 22-3023093 (State or Other Jurisdiction of Incorporation) |
|
| March 2, 2016 |
CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL 2015 Press Release Exhibit 99.1 For Immediate Release Contact: David Portnoy Cryo-Cell International, Inc. 813-749-2100 [email protected] CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL 2015 OLDSMAR, Fla. ? March 2, 2016 ? Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the ?Company?), the world?s first private cord blood bank to separate and store stem cells in 1992, announced r |
|
| March 2, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 2, 2016 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation |
|
| February 29, 2016 |
Third Lease Amendment by and between the Company and EJB Brooker Creek, LLC Exhibit 10. |
|
| February 29, 2016 |
CCEL / CRYO-CELL International, Inc. 10-K - Annual Report - FORM 10-K Form 10-K U.S. Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended November 30, 2015 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number 000-23386 CRYO-CELL INTERNATIONAL, INC. (Exact N |
|
| October 15, 2015 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q Form 10-Q Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended August 31, 2015 ¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 0- |
|
| July 30, 2015 |
CRYO-CELL, CORD BLOOD BANKING COMPANY, ANNOUNCES FINAL RESULTS OF ITS TENDER EX-99.(A)(5)(II) 2 d81660dex99a5ii.htm PRESS RELEASE Exhibit (a)(5)(ii) For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 [email protected] CRYO-CELL, CORD BLOOD BANKING COMPANY, ANNOUNCES FINAL RESULTS OF ITS TENDER OFFER OLDSMAR, Fla. – July 30, 2015 – Cryo-Cell International, Inc. (the “Company”) (OTC:QB Markets |
|
| July 30, 2015 |
CRYO-CELL International AMENDMENT NO.1 TO SCHEDULE TO Amendment No.1 to Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 1) (RULE 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR SECTION 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CRYO-CELL INTERNATIONAL, INC. (Name of Subject Company (Issuer)) CRYO-CELL INTERNATIONAL, INC. (Name of Filing Person (Offeror)) COMMON STOCK, PAR V |
|
| July 17, 2015 |
CRYO-CELL REPORTS FISCAL SECOND QUARTER 2015 FINANCIAL RESULTS Press Release Exhibit 99.1 For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 [email protected] CRYO-CELL REPORTS FISCAL SECOND QUARTER 2015 FINANCIAL RESULTS OLDSMAR, Fla. ? July 16, 2015 ? Cryo-Cell International, Inc. (the ?Company?) (OTC:QB Markets Group Symbol: CCEL), the world?s first private cord blood bank to |
|
| July 17, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 16, 2015 CRYO CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation) (Commis |
|
| July 16, 2015 |
Amendment No. 1 to Asset Purchase Agreement dated June 30, 2015 Asset Purchase Agreement Amendment No 1 Exhibit 2 AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT THIS AMENDMENT (this ?Amendment?), made as of June 30, 2015 by and between CytoMedical Design Group LLC, a Minnesota limited liability (?Seller?), and Cryo-Cell International, Inc., a Delaware corporation (?Purchaser?), hereby amends that certain Asset Purchase Agreement between Seller and Purchaser dated |
|
| July 16, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 30, 2015 CRYO-CELL International, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-23386 22-3023093 (State or Other Jurisdiction of Incorporation) (Commis |
|
| July 15, 2015 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q Form 10-Q Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended May 31, 2015 ¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number 0-233 |
|
| July 13, 2015 |
CRYO-CELL International FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 9, 2015 CRYO-CELL INTERNATIONAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-23386 22-3023093 (State or Other Jurisdiction of Incorporation) ( |
|
| June 30, 2015 |
CRYO-CELL International SCHEDULE TO Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR SECTION 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CRYO-CELL INTERNATIONAL, INC. (Name of Subject Company (Issuer)) CRYO-CELL INTERNATIONAL, INC. (Name of Filing Person (Offeror)) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class |
|
| June 30, 2015 |
EX-99.(A)(1)(I) 2 d949843dex99a1i.htm OFFER TO PURCHASE, DATED JUNE 30, 2015 Table of Contents Exhibit (a)(1)(i) OFFER TO PURCHASE FOR CASH BY CRYO-CELL INTERNATIONAL, INC. OF UP TO 750,000 SHARES OF ITS COMMON STOCK AT A PURCHASE PRICE OF $3.25 PER SHARE THE TENDER OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 12:00 MIDNIGHT (ONE MINUTE AFTER 11:59 P.M.), NEW YORK TIME, ON JULY 28, 2015, UNLESS THE |
|
| June 30, 2015 |
Youâve Exceeded the SECâs Traffic Limit Letter of Transmittal Exhibit (a)(1)(ii) LETTER OF TRANSMITTAL To tender shares of common stock Pursuant to the Offer to Purchase for cash dated June 30, 2015 BY CRYO-CELL INTERNATIONAL, INC. |
|
| June 30, 2015 |
CRYO-CELL INTERNATIONAL, INC. NON-QUALIFIED STOCK OPTION AGREEMENT 2012 Equity Incentive Plan Non-Qualified Stock Option Agreement EXHIBIT (d)(8) OPTION NO. |
|
| June 30, 2015 |
Youâve Exceeded the SECâs Traffic Limit Press Release Exhibit (a)(5)(i) Cryo-Cell Commences Tender Offer to Purchase its Common Stock Up to 750,000 Shares at $3. |
